Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;196(4):963-968.
doi: 10.1111/bjh.17906. Epub 2021 Oct 25.

Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia

Zaid H Abdel Rahman  1 , Ricardo D Parrondo  1 , Michael G Heckman  2 , Mikolaj Wieczorek  2 , Kevin C Miller  3 , Hassan Alkhateeb  4 , Lisa Z Sproat  5 , Hemant Murthy  1 , William J Hogan  4 , Mohamed A Kharfan-Dabaja  1 , Jess F Peterson  6 , Linda B Baughn  6 , Nicole Hoppman  6 , Mark R Litzow  4 , Rhett P Ketterling  6 , Patricia T Greipp  6 , James M Foran  1
Affiliations

Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia

Zaid H Abdel Rahman et al. Br J Haematol. 2022 Feb.

Abstract

We report a comparative analysis of patients with therapy-related acute lymphoblastic leukaemia (tr-ALL) vs de novo ALL. We identified 331 patients with B-ALL; 69 (21%) were classified as tr-ALL. The most common prior malignancies were breast (23·2%) and plasma cell disorders (20·3%). Patients with tr-ALL were older (median 63·2 vs. 46·2 years, P < 0.001), more often female (66·7% vs. 43·5%, P < 0·001), and more likely to have hypodiploid cytogenetics (18·8% vs. 5·0%, P < 0·001). In multivariable analysis, patients with tr-ALL were less likely to achieve complete remission [odds ratio (OR) = 0·16, P < 0·001] and more likely to be minimal residual disease-positive (OR = 4·86, P = 0·01) but had similar OS after diagnosis and allo-haematopoietic cell transplantation.

Keywords: ALL; FISH; leukemia; therapy-related.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant conflicts of interest.

References

    1. Swaika A, Frank RD, Yang D, Finn LE, Jiang L, Advani P, et al. Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes. Cancer Med. 2018;7(2):499–507. - PMC - PubMed
    1. Rosenberg AS, Brunson A, Paulus JK, Tuscano J, Wun T, Keegan THM, et al. Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. Blood Cancer J. 2017;7(9):e605. - PMC - PubMed
    1. Aldoss I, Dagis A, Palmer J, Forman S, Pullarkat V. Therapy‐related ALL: cytogenetic features and hematopoietic cell transplantation outcome. Bone Marrow Transplant. 2015;50(5):746–8. - PubMed
    1. Kelleher N, Gallardo D, González‐Campos J, Hernández‐Rivas JM, Montesinos P, Sarrá J, et al. Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy. Leukemia & Lymphoma. 2016;57(1):86–91. - PubMed
    1. Aldoss I, Stiller T, Tsai N‐C, Song JY, Cao T, Bandara NA, et al. Therapy‐related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica. 2018;103(10):1662–8. 10.3324/haematol.2018.193599 - DOI - PMC - PubMed

Publication types